THE AMERICA ONE NEWS
Jun 22, 2025 |
0
| Remer,MNSponsor: QWIKET
Sponsor: QWIKET
Sponsor: QWIKET: Sports Knowledge
Sponsor: QWIKET: Elevate your fantasy game! Interactive Sports Knowledge.
Sponsor: QWIKET: Elevate your fantasy game! Interactive Sports Knowledge and Reasoning Support for Fantasy Sports and Betting Enthusiasts.
topic
America One News
2 Feb 2025
#society
GB News: Terrifying moment camo-clad man aims 'assault rifle' at London Underground train
A man in his 20s was arrested at Whitechapel Station in London for brandishing an imitation sniper rifle while in combat gear, alarming commuters. He was heading to a film and comic convention when the incident occurred. He has since been released on bail.
British Transport Police emphasized the importance of keeping prop weapons concealed during travel to avoid panic and disruption. They receive numerous reports about weapon sightings during events like Comic Con and urge attendees to be mindful of their actions in public spaces.
#economy
GB News: Ryanair launches 7 new routes from the UK to France, Turkey and more destinations starting this summer
Ryanair is expanding its London operations for summer 2025, adding seven new routes from Stansted Airport and increasing flights on 30 existing routes. This expansion includes new services to destinations in Europe and Turkey, with a £78.5 million investment and the addition of a Boeing 737.
CEO Michael O'Leary criticized a planned £2 increase in Air Passenger Duty (APD) on short-haul flights, arguing it could hinder growth at UK airports. The expansion will create 30 new jobs and enhance connectivity to popular destinations like Ibiza and Malaga.
#health
Fox News: FDA approves opioid-free pain medication with 'no sign of addiction'
The FDA has approved Journavx (suzetrigine), a non-opioid medication for moderate to severe acute pain, offering a non-addictive alternative to opioids. This marks a significant development in pain management, addressing a major unmet need as over 80 million Americans suffer from acute pain annually.
Journavx works by inhibiting sodium channels rather than modifying brain receptors, reducing risks of dependency and side effects. It has shown high patient satisfaction in trials and will be covered under the NOPAIN Act starting January 2025, enhancing access to this safer pain management option.